Join
Live feed
·
PRReleasevia Quantisnow
Medicinova Inc logo

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

ByQuantisnow·Wall Street's wire, on your screen.
MNOV· Medicinova Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNOV (Medicinova Inc) and more on Quantisnow.